Aldeyra Therapeutics, Inc.
ALDXDrugs in Pipeline
16
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
24dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How ALDX's past catalysts played out
Reproxalap Ophthalmic Solution (0.5%)
Allergic Conjunctivitis
ADX-102 1% Topical Dermal Cream (reproxalap)
Sjogren-Larsson Syndrome
ADX-2191 (intravitreal methotrexate 0.8%)
Proliferative Vitreoretinopathy
Reproxalap Ophthalmic Solution (0.25%) QID
Dry Eye
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Dry Eye
ADX-102 Ophthalmic Solution (0.5%)
Dry Eye Syndromes
Reproxalap Ophthalmic Solution (0.25%)
Dry Eye Syndromes
Reproxalap Ophthalmic Solution (0.1%)
Dry Eye Syndrome
Active topical NS2 1% dermatologic cream
Sjögren-Larsson Syndrome
NS2
Non-infectious Anterior Uveitis
ADX-102 Ophthalmic Drops (0.5%)
Conjunctivitis, Allergic
ADX-2191
Retinitis Pigmentosa
ADX-629
Ethanol Intoxication
ADX-629 (Open-label)
Atopic Dermatitis
Xiidra® (5% lifitegrast ophthalmic solution)
Dry Eye
NS2 Ophthalmic Drops (0.5%)
Allergic Conjunctivitis
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aldeyra Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in Aldeyra Therapeutics, Inc.'s (ALDX) pipeline across Phase 3, Phase 2. Its lead program is Reproxalap Ophthalmic Solution (0.5%) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aldeyra Therapeutics, Inc.'s next FDA catalyst?→
Aldeyra Therapeutics, Inc.'s (ALDX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALDX biotech catalysts?→
Add ALDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aldeyra Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.